Acorda Therapeutics, Inc. (ACOR)

Beiträge: 72
Zugriffe: 12.874 / Heute: 1
Acorda Therapeut. 4,775 € -0,73% Perf. seit Threadbeginn:   -95,62%
 
Acorda Therapeutics, Inc. (ACOR) Chalifmann3
Chalifmann3:

Acorda Therapeutics, Inc. (ACOR)

 
07.02.17 05:27
#1

https://marketexclusive.com/...-run-money-migraine-drug-market/69612/

Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich

... (automatisch gekürzt) ...

https://marketexclusive.com/...-run-money-migraine-drug-market/69612/
Moderation
Zeitpunkt: 07.02.17 13:44
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen

Link: Forumregeln  

Acorda Therapeutics, Inc. (ACOR) Chalifmann3
Chalifmann3:

Profil

 
07.02.17 06:41
#2

http://finance.yahoo.com/quote/ACOR/profile?p=ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders

... (automatisch gekürzt) ...

http://finance.yahoo.com/quote/ACOR/profile?p=ACOR
Moderation
Zeitpunkt: 07.02.17 13:45
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen

Link: Forumregeln  

Acorda Therapeutics, Inc. (ACOR) Chalifmann3
Chalifmann3:

news

 
10.02.17 16:16
#3
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods in people with Parkinson’s disease taking an oral carbidopa / levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms.

“We are greatly encouraged by the efficacy and safety results of this trial, which validate the positive Phase 2b results,” said Burkhard Blank, M.D., Chief Medical Officer of Acorda. “We would like to express our gratitude to the study volunteers and clinical investigators who participated in this trial to advance our understanding of this potentially important therapy for people with Parkinson’s.”

The SPAN-PD trial had three arms: CVT-301 84 mg and 60 mg doses (equivalent to 50 mg and 35 mg fine particle doses, respectively), and placebo. The primary endpoint of the study was the change at Week 12 in Unified Parkinson’s Disease Rating Scale-Part 3 (UPDRS III) score relative to placebo at 30 minutes post-treatment for the 84 mg dose. UPDRS III change for the 84 mg dose was -9.83 compared to -5.91 for placebo (p=0.009). UPDRS III is a validated scale, which measures Parkinson’s motor impairment.

The safety profile of CVT-301 in this study was consistent with that observed in the Phase 2b trial. Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) tests showed no notable pulmonary safety signals. The Company is currently conducting two studies to assess the long-term safety profile of CVT-301. Up to 12-month data from these studies are expected by the end of the first quarter of 2017.

The Company plans to file a New Drug Application (NDA) in the United States by the end of the second quarter of 2017, pending results of the long-term safety studies. The Company also plans to file a Marketing Authorization Application (MAA) in Europe by the end of 2017, pending additional data analyses.

Peter LeWitt, M.D., M.Med.Sc., Director of the PD and Movement Disorders Program at Henry Ford Hospital and lead investigator of the study said, “The re-emergence of Parkinson’s disease symptoms has a major negative impact on the lives of people with this disease, as well as on their families and care partners. Managing symptoms of OFF periods continues to be a significant unmet need for people taking oral carbidopa/levodopa regimens. Delivering levodopa by the pulmonary route offers an important treatment option for people with Parkinson’s disease.”

Detailed trial results will be presented at a future medical meeting.
Acorda Therapeutics, Inc. (ACOR) Balu4u
Balu4u:

positive parkinson results

 
06.06.17 12:17
#4
seekingalpha.com/news/...tive-results-parkinsons-disease-drug
Acorda Therapeutics, Inc. (ACOR) InterHorst
InterHorst:

Insiderkäufe

 
21.06.17 13:39
#5
Gab es dann gestern auch schon! Könnte bald richtig rocken hier!
Acorda Therapeutics, Inc. (ACOR) InterHorst
InterHorst:

läuft klasse

 
24.07.17 19:29
#6
Acorda Therapeutics, Inc. (ACOR) Balu4u
Balu4u:

Buy rating

 
02.05.18 22:05
#7
www.analystratings.com/articles/...a-buy-rating-from-cowen-co/
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 21,20$ (-23%)

 
10.09.18 18:20
#8
www.streetinsider.com/Corporate+News//...atents/14592158.html
Der ARIVA.DE Newsletter
Bleiben Sie informiert mit dem
wöchentlichen Marktüberblick
von ARIVA.DE!
E-Mail-Adresse
Ich möchte Benachrichtigungen von ARIVA.DE erhalten.
Ja, ich habe die Datenschutzhinweise gelesen und akzeptiert (Pflichtfeld).
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 13,41$

 
26.12.18 16:38
#9

FDA erteilt Zulassung, Aktien interessiert es nicht

endpts.com/...da-ok-so-does-that-make-them-a-takeover-target/

Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 14,35$ (-8%)

 
15.02.19 16:25
#10

Acorda meldet Zahlen für 2018

  • Q4/18 Umsätze  ~69 Mio. $ (vgl. 188 Mio. $ in Q4/17)
    • Ampyra verlor Exklusivität
    • Generika eroberten den Markt
  • 2018 Umsätze ~471 Mio. $ (vgl. 588 Mio. $)
  • Q4/18 Gewinn ~10 Mio. $ (EPS 0,20$)
  • 2018 Gewinn ~34 Mio. $ (EPS 0,71$)

ir.acorda.com/investors/investor-news/...End-2018/default.aspx


Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 12,53$ (neues 52 Wochen-Tief)

 
10.04.19 16:48
#11
seekingalpha.com/news/...cs-chief-business-officer-bids-adieu
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 11,29$

 
18.04.19 16:40
#12
sucht weiter seinen Boden
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 10,05$ (-4%)

 
02.05.19 15:38
#13

Ampyra Umsätze fallen um 60%

  • Umsätze 44 Mio. $
  • Verlust 48 Mio. $
  • Cash 343 Mio. $
  • MK 479 Mio. $

ir.acorda.com/investors/investor-news/...-31-2019/default.aspx


Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 9,38$

 
31.05.19 14:52
#14
  • neues 52 Wochen-Tief bei 9,25$ markiert
  • MK 451 Mio. $
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 8,65$

 
06.06.19 15:20
#15
  • neues 52 Wochen-Tief
  • MK 416 Mio. $
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 7,16$

 
13.06.19 15:34
#16
  • neues 52 Wochen-Tief
  • MK 345 Mio. $
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 6,07$ (-12%)

 
02.08.19 09:50
#17

Acorda Therapeutics meldet Zahlen für Q2/19

  • Umsatz 50 Mio. $
  • Verlust 27 Mio. $
  • Cash 297 Mio. $
  • MK 292 Mio. $
  • MK = Cash

ir.acorda.com/investors/investor-news/...-30-2019/default.aspx

seekingalpha.com/news/...peutics-eps-beats-0_51-beats-revenue

Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 3,31$ (-45%)

 
02.08.19 16:41
#18
  • neues 52 Wochen-Tief
  • MK 159 Mio. $
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

AMPYRA

 
02.08.19 16:56
#19

"In September 2018, AMPYRA lost its exclusivity and generics entered the market. Consequently, the Company expects AMPYRA revenue to continue to decline"

  • Ampyra ~44 Mio. $ in Q2/19 von 150 Mio. $ in Q2/18

ir.acorda.com/investors/investor-news/...-30-2019/default.aspx

Acorda Therapeutics, Inc. (ACOR) Rudini
Rudini:

Abschlag scheint übertrieben

 
02.08.19 17:43
#20
Ok, die Exklusivitätsrechte sind weg. Allerdings ist der Cashbestand doppelt so hoch wie die Mk...
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 2,45$ (-10%)

 
14.08.19 16:24
#21
Wenn Generika auf den Markt kommen, dann sind Umsatzeinbrüche vorprogrammiert, darauf hat Acorda ja schon deutlich hingewiesen. Weniger Umsatz = mehr Verlust, bei gleichbleibenden Kosten. Hier fehlen zur Zeit einfach die positiven Katalysatoren. MK 118 Mio. $, aber wie will ACOR gegen den Trend stemmen? Neues 52 Wochen-Tief!
Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 2,47$ (-9%, vorbörslich)

 
24.10.19 13:57
#22

Restrukturierung --> 25% der Belegschaft soll entlassen werden

ir.acorda.com/investors/investor-news/...9-Update/default.aspx

Acorda Therapeutics, Inc. (ACOR) Vassago
Vassago:

ACOR 1,80$ (-10%, neues 52 Wochen-Tief)

 
25.10.19 16:31
#23

Hier die vorraussichtlichen Umsatzzahlen für Q3/19

  • INBRIJA 4,9 Mio. $ (kommerziell verfügbar seit 03/19)  
  • AMPYRA 37,6 Mio. $
    • Vergleiche mit 137,8 Mio. $ in Q3/18  
  • Cash 253 Mio. $
  • MK 87 Mio. $

Ausblick Ausgaben 2019 vs. 2020

  •  R&D expenses for the full year 2019 are expected to be $55 - $60 million,
    • reduced from $70 - $80 million
  • SG&A expenses for the full year 2019 are expected to be $185 - $190 million,
    • reduced from $200 - $210 million  
  • R&D expenses for the full year 2020 are expected to be $20 - $25 million
  • and SG&A expenses for the full year 2020 are expected to be $160 - $165 million  
Acorda Therapeutics, Inc. (ACOR) Steffen68ffm
Steffen68ffm:

Super

 
01.11.19 19:44
#24
Habe gestern 4000 gekauft und dann gleich 3000 wieder zu 1,47 verkauft und heute für 1,59.
Man könnte ich mich ärgern. Allerdings findet man ganz schwer Nachrichten und Meldungen.
Acorda Therapeutics, Inc. (ACOR) Balu4u
Balu4u:

Nach Zahlen gehts hoch

 
06.11.19 10:30
#25
seekingalpha.com/news/3514674-acorda-21-percent-q3-beat

Seite: Übersicht Alle 1 2 3 WeiterWeiter

Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Acorda Therapeutics Forum

  
Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  71 Acorda Therapeutics, Inc. (ACOR) Chalifmann3 klausy 22.01.21 10:58
  23 Acorda Therapeutic bricht aus Tiger Tiger 24.12.20 02:01
    FDA-Beirat - 12:1 für Fampridin-Zulassung bei MS LupusBXL   15.10.09 10:57
  4 Hammer -Aktie hhsjgmr buran 09.10.06 09:39

--button_text--